As a virulent lung disease that is believed to be caused by both smoking and air pollution, COPD, or Chronic Obstructive Pulmonary Disease, is a serious health threat. In the United States COPD is deemed the third leading cause of death as of 2015, with roughly 600 million people worldwide suffering from this debilitating disease. Characterized by chronic airway inflammation and a progressive loss of lung function, COPD now accounts for fifty billion dollars in treatment costs for the U.S. alone. The severe exacerbations that the majority of patients with COPD suffer from cause a plethora of adverse effects, ranging from breathlessness to difficulty performing any tasks requiring physical exertion. People enduring severe exacerbations on a regular basis are almost forty percent likely to die within a year from these events, and two-thirds of these patients will perish within three years’ time. The need for both novel and continuous treatment options is great, and Vilanterol has continued to fill this need for many years.
Known as an integral part of the brand name inhaler Breo Ellipta, Vilanterol works in tandem with Fluticasone Furoate as an effectual long-acting beta2-adrenergic agonist. Marketed by GlaxoSmithKline and Theravance, Breo Ellipta is FDA approved to treat adults with COPD. Vilanterol and Fluticasone Furoate have proven to be a dynamic duo for reducing exacerbations in patients with COPD, and aiding patients with airflow obstruction issues. The use of this once a day inhaled therapy is ideal for a safe and tolerable long term treatment option. Breo Ellipta is actually the first FDA-approved inhaled therapy to be used once daily for COPD patients that contains both a corticosteroid and long-acting beta2-adrenergic agonist. Adverse events in clinical trials and post market studies have been rare, with common side effects noted being oral candidiasis and mild nasal irritation.
The ability of Vilanterol to contribute to 24 hour control, alongside Fluticasone Furoate, makes this combination a novel and viable treatment for COPD patients. With almost 13 million Americans currently diagnosed with this devastating disease COPD has become an emerging condition which research and development teams are seeking to find treatments for. LGM Pharma can assist clients as a supplier/distributor of the API Vilanterol, CAS # 503070-58-4 and also Fluticasone Furoate, CAS # 397864-44-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.